ARTELO BIOSCIENCES, INC. 8-K

What Happened Artelo Biosciences, Inc. (ARTL) filed an 8-K reporting the reconvened Annual Meeting of Stockholders held January 30, 2026 (record date Dec 10, 2025). Of 2,018,746 shares outstanding, 1,017,816 shares (≈50.4%) were represented, providing a quorum after the meeting had been adjourned on Dec 31, 2025 for lack of sufficient votes. Shareholders re-elected two Class II directors — Douglas Blayney, M.D. and Connie Matsui — approved the advisory “say-on-pay” executive compensation proposal, and ratified Malone Bailey LLP as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Shares and quorum: 2,018,746 shares outstanding; 1,017,816 shares (≈50.4%) represented at the reconvened meeting.
• Director elections (terms to 2028): Douglas Blayney — For 248,985; Withhold 139,452; Broker non-votes 633,102. Connie Matsui — For 257,384; Withhold 131,053; Broker non-votes 633,102.
• Advisory vote on executive compensation (say‑on‑pay): For 158,971; Against 126,089; Abstain 103,377; Broker non‑votes 633,102.
• Ratification of auditor: Malone Bailey LLP ratified for fiscal year ending Dec 31, 2026 — For 830,673; Against 85,078; Abstain 102,065.

Why It Matters The results confirm board continuity with two Class II directors re-elected and demonstrate shareholder approval (advisory) of the company’s executive pay approach. Ratifying Malone Bailey LLP ensures continuity in external audit services for the coming fiscal year, a practical governance detail for investors monitoring financial reporting. The meeting also highlights that shareholder participation was just above 50%, a reminder of the impact of broker non‑votes and turnout on corporate governance outcomes.